In the last section I cover: Lillys business model Lillys competitive advantage Lillys competitors and how they stack up Risks and headwinds Deep dive into the financials My bear/base and bull case valuation models My plan and approach for Eli Lilly and the GLP-1 sector
With that in mind, we have studied pathways involving insulin, ghrelin, and GLP-1, he says
Fewer or More Manageable Side Effects Many people explore microdosing GLP-1 medications in hopes of reducing common GLP-1 side effects such as nausea, vomiting, diarrhea, and appetite suppression
The AWARE-2 study
Because of this, its not known for sure if Synjardy is safe or effective for people less than 18 years old
It stems from a shift in medicine towards more personalized, regenerative treatments